Advanced Accelerator Application SA (NASDAQ:AAAP) has inked a NETSPOT distribution deal with Cardinal Health Inc (NYSE:CAH), bringing to two the number of partners tapped to supply the patented ...

SAINT-GENIS-POUILLY, France, May 18, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM) ...

The Food and Drug Administration (FDA) has approved Netspot (Advanced Accelerator Applications), a radioactive diagnostic agent for positron emission topography (PET) imaging. The probe will aid in ...

After earning priority review status, the French-based pharmaceutical company Advanced Accelerator Applications just received FDA approval for a new agent to image neuroendocrine tumors (NET).

Please provide your email address to receive an email when new articles are posted on . The FDA approved the diagnostic imaging agent Netspot to detect rare neuroendocrine tumors. Netspot (Advanced ...

Insurance Australia Group posted higher annual cash earnings on Wednesday, beating estimates, as increased premiums and lower-than-expected natural peril costs improved performance and allowed the top ...

The FDA has approved a novel PET imaging diagnostic agent for neuroendocrine tumors from Advanced Accelerator Applications ($AAAP). The nod comes 7 months after the ...

$3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera ®) for GEP-NETs Recent Highlights: SAINT-GENIS-POUILLY, France, Nov. 17, 2017 (GLOBE ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA approved Netspot, the first kit ...

* Advanced Accelerator Applications Announces FDA Approval Of Netspot(Tm) (Somakit-tate), a kit for the preparation of Gallium GA 68 Dotatate for neuroendocrine tumor detection Sign up here. * ...